The company said it will use the proceeds for the US commercial launch of its Unyvero molecular diagnostic platform, among other things.
The company recently disclosed that the commercial launch of its liquid biopsy lung cancer diagnostic had been delayed.
The firm increased the number of shares it was offering after its stock price fell sharply this week.
JP Morgan Securities and Cowen and Company are the joint book-running managers for the offering, while William Blair is the lead manager.
The company had intended to raise up to €6.6 million through the placement to help fund its planned acquisition of TGR Biosciences.
Sygnis said that TGR is profitable and has a complementary product portfolio that includes protein capture technology.
The firm plans to use net proceeds for corporate purposes, including capital expenditures and working capital.
The firm plans to use the $13.3 million in net proceeds to fund ongoing operations, expansions of its liquid biopsy business, and to service its indebtedness.
The company plans to use proceeds to support its ongoing operations, expansion of its business, and to service existing debts.
The company said it anticipates using net proceeds for working capital and general corporate purposes.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more